COUR Pharmaceuticals aims to advance novel therapies that reprogram the immune system for antigen-specific tolerance, focusing on the root of immune-mediated diseases. Their cutting-edge nanoparticle platform diverges from traditional symptom-suppressing treatments, offering a more targeted approach. Collaborating with Takeda on a leading celiac disease therapy, COUR has achieved the first instance of antigen-specific immune tolerance in autoimmune diseases. This breakthrough underscores the potential of their platform to address a wide array of immune and inflammatory conditions.
Cour Pharmaceuticals Development is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Cour Pharmaceuticals Development pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Cour Pharmaceuticals Development is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.